AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15196155 — intervention group
Group type: COMPARATOR
Intervention: Intravenous benzyl penicillin (4 MU x 6 times daily)
Number of subjects: 112
Study 15196155 — intervention group
Group type: COMPARATOR
Intervention: Intravenous benzyl penicillin
Number of subjects: 112
Study 15196155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular penicillin
Number of subjects: 112
Study 11604648 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (two applications)
Number of subjects: 10
Study 11604648 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium laser (two applications)
Number of subjects: 10
Study 11604648 — intervention group
Group type: COMPARATOR
Intervention: Erbium laser (one application)
Number of subjects: 10
Study 11604648 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser (one application) + Erbium laser (one application)
Number of subjects: 10
Study 9405029 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464
Study 9405029 — intervention group
Group type: EXPERIMENTAL
Intervention: Vit D3 (vitamin D3 300 IU/day)
Number of subjects: 464
Study 9405029 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT+Vit D3 (both as above)
Number of subjects: 464
Study 9405029 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium lactate 500 mg/day)
Number of subjects: 464
Study 2873324 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers (94 patients)
Number of subjects: 272
Study 2873324 — intervention group
Group type: COMPARATOR
Intervention: Control patients (178 patients)
Number of subjects: 272
Study 31292219 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational handout about influenza disease (local data)
Number of subjects: 0
Study 31292219 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational handout about influenza disease (national data)
Number of subjects: 0
Study 31292219 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 27881551 — intervention group
Group type: EXPERIMENTAL
Intervention: CR‐Equipements™ solid ankle cushion heel foot with polypropylene keel
Number of subjects: 15
Study 27881551 — intervention group
Group type: COMPARATOR
Intervention: solid ankle cushion heel foot with wooden keel (Otto Bock)
Number of subjects: 15
Study 26177352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N9) gel
Number of subjects: 27
Study 26177352 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal placebo gel (UPG)
Number of subjects: 27
Study 26177352 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 27
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-sintered Co-Cr (LS)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-cast Co-Cr (CC)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-cast Ni-Cr-Ti (CN)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji PLUS (FP)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: DentoTemp (DT)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement (CEC)
Number of subjects: 45
Study 23022105 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem 2 Automix (RXU)
Number of subjects: 45
Study 22229185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg/d
Number of subjects: 119
Study 22229185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 119
Study 18927254 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation
Number of subjects: 154
Study 18927254 — intervention group
Group type: COMPARATOR
Intervention: Subsequent surgical procedures
Number of subjects: 154
Study 17467059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 193
Study 17467059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone in combination with interpersonal psychotherapy (IPT)
Number of subjects: 193
Study 17467059 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT in combination with placebo
Number of subjects: 193
Study 17467059 — intervention group
Group type: EXPERIMENTAL
Intervention: IPT alone
Number of subjects: 193
Study 17467059 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo with IPT)
Number of subjects: 193
Study 15641632 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 60
Study 15641632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11719944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ndu tea extract
Number of subjects: 30
Study 11719944 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipton tea extract
Number of subjects: 30
Study 11719944 — intervention group
Group type: COMPARATOR
Intervention: Minty Brett (thymol 0.047%)
Number of subjects: 30
Study 11719944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tea extracts with sodium lauryl sulfate (1.2% w/v)
Number of subjects: 30
Study 9207726 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray, 50 micrograms to each nostril, bid for 3 weeks
Number of subjects: 151
Study 9207726 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray, bid for 3 weeks
Number of subjects: 151
Study 8432773 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.25-0.5 U/kg.week, administered sc daily at bedtime)
Number of subjects: 10
Study 8432773 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 10
Study 3435129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefodizime (1 g)
Number of subjects: 6
Study 3435129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cefodizime (1 g)
Number of subjects: 6
Study 29520947 — intervention group
Group type: COMPARATOR
Intervention: Negative partner control provided by women (T0)
Number of subjects: 113
Study 29520947 — intervention group
Group type: COMPARATOR
Intervention: Negative partner control provided by men (T0)
Number of subjects: 113
Study 29520947 — intervention group
Group type: COMPARATOR
Intervention: Negative partner control provided by partners (T2)
Number of subjects: 113
Study 26890440 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum antibiotic prophylaxis
Number of subjects: 80
Study 26890440 — intervention group
Group type: COMPARATOR
Intervention: No treatment following delivery
Number of subjects: 80
Study 26890440 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CD antibiotics (meta-analysis)
Number of subjects: 80
Study 26890440 — intervention group
Group type: COMPARATOR
Intervention: No treatment (meta-analysis)
Number of subjects: 80
Study 25124305 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)‐THC (30 mg)
Number of subjects: 10
Study 25124305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 10
Study 25124305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 10
Study 25124305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg) + Δ(9)‐THC (5, 15, 30 mg)
Number of subjects: 10
Study 25124305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg) + Δ(9)‐THC (5, 15, 30 mg)
Number of subjects: 10
Study 25124305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22562732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training sessions (Group A) for the first 6 weeks of a 12-week training program.
Number of subjects: 43
Study 22562732 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training (Group B) for the first 6 weeks of a 12-week training program.
Number of subjects: 43
Study 22562732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups allowed to conduct high-intensity training in the second 6-week period.
Number of subjects: 43
Study 22562732 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental laboratory test measuring GE and V˙O2max.
Number of subjects: 43
Study 20352087 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based maternal and newborn interventions including two antenatal home visits and four postnatal home visits by community health workers.
Number of subjects: 9987
Study 20352087 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison arm) with no specific intervention mentioned.
Number of subjects: 9987
Study 18794654 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/d)
Number of subjects: 121
Study 18794654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 16320437 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific computer intervention (GSI)
Number of subjects: 0
Study 16320437 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Inserts
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Footwear
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 12192263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy
Number of subjects: 0
Study 10642057 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (100 mg/kg per 24 h per os)
Number of subjects: 230
Study 10642057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 7775065 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning spelling instruction
Number of subjects: 113
Study 7775065 — intervention group
Group type: COMPARATOR
Intervention: Afternoon spelling instruction
Number of subjects: 113
Study 2150366 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 33
Study 2150366 — intervention group
Group type: COMPARATOR
Intervention: r-TPA
Number of subjects: 33
Study 493093 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol
Number of subjects: 34
Study 493093 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol in combination with a diuretic
Number of subjects: 34
Study 493093 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 31272901 — intervention group
Group type: EXPERIMENTAL
Intervention: Relocation pharyngoplasty with platelet-rich fibrin (PRF)
Number of subjects: 30
Study 31272901 — intervention group
Group type: COMPARATOR
Intervention: Classic relocation pharyngoplasty
Number of subjects: 30
Study 31185905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group U)
Number of subjects: 300
Study 31185905 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator guidance (group N)
Number of subjects: 300
Study 31185905 — intervention group
Group type: COMPARATOR
Intervention: Dual guidance (group M)
Number of subjects: 300
Study 28035445 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-impact exercise
Number of subjects: 80
Study 28035445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 25858497 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib plus gemcitabine (masitinib 9 mg/kg/day, gemcitabine 1000 mg/m²)
Number of subjects: 353
Study 25858497 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine (placebo, gemcitabine 1000 mg/m²)
Number of subjects: 353
Study 25858497 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib plus gemcitabine in ACOX1 subgroup
Number of subjects: 353
Study 25858497 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib plus gemcitabine in pain subgroup (VAS > 20 mm)
Number of subjects: 353
Study 22647197 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week leadership intervention (workshop, teleconferences)
Number of subjects: 0
Study 22647197 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 20727239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium and vitamin D supplementation for low bone density (LBD) women.
Number of subjects: 56
Study 19386548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose PCI (25 Gy in 10 daily fractions of 2.5 Gy)
Number of subjects: 720
Study 19386548 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose PCI (36 Gy delivered using either conventional or accelerated hyperfractionated radiotherapy)
Number of subjects: 720
Study 19386548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose PCI (25 Gy)
Number of subjects: 720
Study 19386548 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose PCI (36 Gy)
Number of subjects: 720
Study 17240089 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-supplemented infant formula
Number of subjects: 52
Study 17240089 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+ARA-supplemented infant formula
Number of subjects: 52
Study 17240089 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 52
Study 17240089 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group
Number of subjects: 52
Study 14597156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid alone (group A)
Number of subjects: 30
Study 14597156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus Vitamin E (group B)
Number of subjects: 30
Study 11294370 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 10 mg
Number of subjects: 48
Study 11294370 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 50 mg
Number of subjects: 48
Study 11294370 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 100 mg
Number of subjects: 48
Study 11294370 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 200 mg
Number of subjects: 48
Study 11294370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9827320 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA prevention workshop
Number of subjects: 45
Study 9827320 — intervention group
Group type: COMPARATOR
Intervention: Workshop on home safety (control)
Number of subjects: 45
Study 7924362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 70
Study 7924362 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 70
Study 2486952 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Reactive Protein (CRP) levels determined by nephelometric technique
Number of subjects: 30
Study 2486952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRM, infection, autoimmune diseases, or chronic inflammation)
Number of subjects: 30
Study 795190 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% diflucortolone valerate ointment
Number of subjects: 52
Study 795190 — intervention group
Group type: COMPARATOR
Intervention: 0.2% flumethasone ointment
Number of subjects: 52
Study 31318772 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery program
Number of subjects: 150
Study 29349868 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive alcohol harm reduction intervention
Number of subjects: 100
Study 29349868 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 100
Study 27378134 — intervention group
Group type: COMPARATOR
Intervention: Chronic inflammation
Number of subjects: 4109
Study 27378134 — intervention group
Group type: COMPARATOR
Intervention: Acute inflammation
Number of subjects: 4109
Study 24488743 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care group
Number of subjects: 89
Study 24488743 — intervention group
Group type: COMPARATOR
Intervention: Care as usual group
Number of subjects: 89
Study 24488743 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized group (NIG)
Number of subjects: 89
Study 24488743 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a history of institutional care
Number of subjects: 89
Study 22251106 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 100 ml.h(‐1) (group R(100))
Number of subjects: 210
Study 22251106 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 200 ml.h(‐1) (group R(200))
Number of subjects: 210
Study 22251106 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 1200 ml.h(‐1) (group R(1200))
Number of subjects: 210
Study 20572767 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 group (SRP + dietary supplementation of fish oil 900 mg EPA + DHA + 81 mg aspirin daily)
Number of subjects: 80
Study 20572767 — intervention group
Group type: COMPARATOR
Intervention: Control group (SRP + placebo)
Number of subjects: 80
Study 18020853 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive distraction via a virtual reality head-mounted display helmet
Number of subjects: 40
Study 18020853 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction via a virtual reality head-mounted display helmet
Number of subjects: 40
Study 18020853 — intervention group
Group type: COMPARATOR
Intervention: No distraction (control group)
Number of subjects: 40
Study 16082528 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 1513
Study 16082528 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment in patients with LVH
Number of subjects: 1513
Study 12692485 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses (30-night extended-wear)
Number of subjects: 139
Study 12692485 — intervention group
Group type: COMPARATOR
Intervention: Conventional hydrogel lenses (6-night extended-wear)
Number of subjects: 139
Study 10609973 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 27
Study 10609973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8542098 — intervention group
Group type: COMPARATOR
Intervention: Specialist journals (206 reports)
Number of subjects: 287
Study 8542098 — intervention group
Group type: COMPARATOR
Intervention: General medical journals (81 reports)
Number of subjects: 287
Study 8542098 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted randomization in specialist journals
Number of subjects: 287
Study 8542098 — intervention group
Group type: COMPARATOR
Intervention: Hypothesis tests in specialist journals
Number of subjects: 287
Study 8542098 — intervention group
Group type: COMPARATOR
Intervention: Hypothesis tests in general journals
Number of subjects: 287
Study 1826569 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel (Marvelon, group A)
Number of subjects: 60
Study 1826569 — intervention group
Group type: COMPARATOR
Intervention: Triphasic oral contraceptive containing 30-40 micrograms ethinyloestradiol and 50-125 micrograms levonorgestrel (Triphasil, group B)
Number of subjects: 60
Study 6791209 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 0
Study 6791209 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6149538 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg/day in two divided doses
Number of subjects: 19
Study 6149538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30997816 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 74
Study 30997816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 74
Study 30997816 — intervention group
Group type: COMPARATOR
Intervention: Hormonal contraceptives (HCs)
Number of subjects: 74
Study 29059542 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT)
Number of subjects: 121
Study 29059542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 121
Study 27858846 — intervention group
Group type: EXPERIMENTAL
Intervention: L + D group (fractional CO2 laser + luliconazole 1% cream)
Number of subjects: 60
Study 27858846 — intervention group
Group type: COMPARATOR
Intervention: L group (fractional CO2 laser alone)
Number of subjects: 60
Study 25171741 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hookworm
Number of subjects: 2345
Study 25171741 — intervention group
Group type: COMPARATOR
Intervention: Maternal hookworm absence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hookworm presence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: COMPARATOR
Intervention: Maternal history of eczema absence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of eczema presence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: COMPARATOR
Intervention: Female gender absence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender presence
Number of subjects: 2345
Study 25171741 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood Trichuris trichiura and hookworm
Number of subjects: 2345
Study 22788235 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop intervention
Number of subjects: 6579
Study 22788235 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-interview intervention
Number of subjects: 6579
Study 22788235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6579
Study 20847065 — intervention group
Group type: EXPERIMENTAL
Intervention: Late remote ischaemic preconditioning (L‐RIPC) consisting of three five-minute cycles of upper limb ischaemia and three five-minute pauses using blood pressure cuff inflation 18 hours prior to the operation.
Number of subjects: 101